Prophylactic Platelet Transfusions in Children with Acute Leukemia: A Dose Response Study

Roy, Albert J.; Jaffe, Norman; Djerassi, Isaac

doi:10.1111/j.1537-2995.1973.tb05490.x

Cited by 117 publications

(80 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Minor bleeding episodes in skin, mucous membranes, microscopic hematuria, guaiac positive stools, and epistaxis were found in approximately 50% of individuals with platelet counts between 0 and 40,000 / p,l but there was no correlation between frequency of bleeding and absolute counts within that range (64). However, serious bleeding (gross bleeding from GI or GU tract) occurred in 26% of the 62 patients with platelet counts between 0 and 10,000 / p,l, 10% between 10,000 and 20,000 / p,l and 4-5% between 20,000 and 40,000 / p,l.…”

Section: )mentioning

confidence: 90%

Controversies in Platelet Transfusion Therapy

Slichter¹

1980

Annu. Rev. Med.

153

View full text Add to dashboard Cite

Section: )mentioning

confidence: 90%

Controversies in Platelet Transfusion Therapy

Slichter¹

1980

Annu. Rev. Med.

153

View full text Add to dashboard Cite

“…5 Roy et al randomly assigned 62 patients to receive 1 of 2 doses, based on units per body weight, when the platelet count was Յ 25 000/L. 1 Both doses were equally efficacious in reducing bleeding incidence, but the small sample size precluded definitive dosing conclusions.…”

Section: Introductionmentioning

confidence: 99%

Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia

Josephson

Granger

Assmann

et al. 2012

Blood

108

View full text Add to dashboard Cite

Age-group analyses were conducted of patients in the prophylactic platelet dose trial (PLADO), which evaluated the relation between platelet dose per transfusion and bleeding. Hospitalized patients with treatment-induced hypoproliferative thrombocytopenia were randomly assigned to 1 of 3 platelet doses: 1.1 ؋ 10 11 , 2.2 ؋ 10 11 , or 4.4 ؋ 10 11 platelets/m 2 per transfusion, given for morning counts of < 10 000 platelets/L. Daily hemostatic assessments were performed. The primary end point (percentage of patients who developed grade 2 or higher World Health Organization bleeding) was evaluated in 198 children (0-18 years) and 1044 adults. Although platelet dose did not predict bleeding for any age group, children overall had a significantly higher risk of grade 2 or higher bleeding than adults (86%, 88%, 77% vs 67% of patients aged 0-5 years, 6-12 years, 13-18 years, vs adults, respectively) and more days with grade 2 or higher bleeding (median, 3 days in each pediatric group vs 1 day in adults; P < .001). The effect of age on bleeding differed by disease treatment category and was most pronounced among autologous transplant recipients. Pediatric subjects were at higher risk of bleeding over a wide range of platelet counts, indicating that their excess bleeding risk may be because of factors other than platelet counts. This trial was registered at www. clinicaltrials.gov as #NCT00128713. (Blood. 2012;120(4):748-760)

show abstract

“…Disadvantages using profi lactic PC therapy include increased number of donor exposures and possibly also enhanced risk of alloimmunzation and refractorines [35,36,10,11]. Th e advantages of profi lactic therapy are still not universaly accepted.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy induced thrombocytopenia treated by four types of platelets concentrates

Nikolić¹,

Nedeljkovic²,

Jelić³

et al. 2015

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

SUMMARYIntroduction: Serious adverse event of anticancer chemotherapy is glanulocytopenia and thrombocytopenia which can decrease effi ciency of fi nal therapy results. After many years, platelet concentrates transfusion (PCT) is still researching problem without sure standpoint. The aim: To determine whether there is a diff erence in the clinical effi ciency in the use of 4 types of platelet applied for transfusion; -to ascertain whether platelet count increase expressed as corrected count increment (CCI), is a better parameter for the evaluation of platelet transfusion effi ciency than the bleeding time (Bt), as the only readily assessable in vivo platelet function related parameter. Subjects and methods: This paper is a part of academic (noncommercial) IV phase observational nointervetion study. Investigation included 78 patients diagnosed with malignant lymphoma and metastatic solid tumors, transfused by platelet concentrates. Patients were devided into 4 groups, based on the type of platelet concentrates used for transfusion. Results: Patients, were transfused with total number of 647 PC units (235 units were non-leukodepleted and 412 units were leukodepleted). Mean number of PC transfusions per patient was 8.3 PC units, and 4.8 PC unit per one transfusion episode. Before PCT: platelets values were: 18

show abstract

Prophylactic Platelet Transfusions in Children with Acute Leukemia: A Dose Response Study

Cited by 117 publications

References 16 publications

Controversies in Platelet Transfusion Therapy

Controversies in Platelet Transfusion Therapy

Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia

Chemotherapy induced thrombocytopenia treated by four types of platelets concentrates

Contact Info

Product

Resources

About